ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 8-K filed 2026-07-30

Filed: 2026-07-30Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 8-KReport period: 2026-07-30SEC accession: 0000872589-26-000023Event: earningsMateriality: 70

Filing text preview

Regeneron Pharmaceuticals reported its second quarter 2026 financial and operating results on July 30, 2026, via a press release furnished as Exhibit 99.1 to the 8-K. The filing does not include specific financial figures.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-07-30Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-2010-Q2026-07-30 · 10-Q10-Q2026-04-29 · 10-Q8-K2026-04-29 · 8-K10-K2026-02-04 · 10-K8-K2026-01-30 · 8-K